Faeth Therapeutics Finalizes Leadership Transition, Rebrands with New Name & Ticker
Summary
Sensei Biotherapeutics, Inc. has officially rebranded as Faeth Therapeutics, Inc. with a new ticker 'FTH', and completed a significant leadership overhaul including a new CEO, CFO, and board appointments, formalizing its post-acquisition strategic pivot.
Key Events
-
Company Rebrands to Faeth Therapeutics
The company officially changed its name from Sensei Biotherapeutics, Inc. to Faeth Therapeutics, Inc., effective June 15, 2026. Its common stock is expected to begin trading under the new Nasdaq ticker symbol 'FTH' on June 16, 2026, formalizing the strategic pivot following the Faeth acquisition.
-
New CEO and CFO Appointed
Anand Parikh, a co-founder of Faeth Therapeutics, was appointed President and Chief Executive Officer, effective June 13, 2026. Brian Stephenson was appointed Chief Financial Officer and principal financial officer on the same date. Christopher W. Gerry will continue as General Counsel and Corporate Secretary.
-
Board of Directors Overhauled
Christopher W. Gerry, Thomas Ricks, and Kristian Humer resigned from the Board. Stephen M. Hahn (former FDA Commissioner) and Saira Ramasastry (life sciences strategic advisor) were appointed as new Class III directors, effective June 12, 2026. The Board size decreased from six to five members, and Anand Parikh was appointed Chair.
-
Old ATM Program Terminated
The company terminated a Prior Sales Agreement with Jefferies LLC, established in March 2022, which allowed for the sale of up to $50 million in common stock. No shares were sold under this agreement prior to its termination.
Analysis
This 8-K marks the definitive completion of Sensei Biotherapeutics' transformation into Faeth Therapeutics, Inc. following its recent acquisition. The formal name and ticker change, coupled with a comprehensive leadership and board refresh, solidify the company's new strategic direction and focus on its PIKTOR program. The appointment of Faeth co-founder Anand Parikh as CEO and Chairman, along with a new CFO and highly qualified independent directors, signals a strong commitment to the new vision. The termination of the old ATM program is a minor cleanup, and the headquarters relocation aligns with the new corporate identity. This filing executes the plans previously outlined in earlier proxy statements and acquisition announcements.
At the time of this filing, SNSE was trading at $12.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.4M. The 52-week trading range was $5.60 to $36.76. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.